Maged Abdel Naseer
- Neurology top 10%
- Peripheral Neuropathies and Disorders 3
- Neurological Disorders and Treatments 3
- Neurological Disease Mechanisms and Treatments 2
-
- Multiple Sclerosis Research Studies 15
-
- Peripheral Neuropathies and Disorders 3
- Neurological Disorders and Treatments 3
- Neurological Disease Mechanisms and Treatments 2
-
- Protease and Inhibitor Mechanisms 3
-
- SARS-CoV-2 and COVID-19 Research 2
-
- Migraine and Headache Studies 2
-
- Alzheimer's disease research and treatments 2
Maged Abdel Naseer
25 papers receiving 276 citations
Peers
Comparison fields: 5 of 84
- Neurology 72
- Biological Psychiatry 21
- Pathology and Forensic Medicine 84
- Neurology 45
- Behavioral Neuroscience 9
Countries citing papers authored by Maged Abdel Naseer
This map shows the geographic impact of Maged Abdel Naseer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maged Abdel Naseer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maged Abdel Naseer more than expected).
Fields of papers citing papers by Maged Abdel Naseer
This network shows the impact of papers produced by Maged Abdel Naseer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maged Abdel Naseer. The network helps show where Maged Abdel Naseer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Maged Abdel Naseer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 5 | |
| 5 | 2023 | 0 | |
| 6 | 2022 | 2 | |
| 7 | 2020 | 11 | |
| 8 | 2020 | 3 | |
| 9 | 2020 | 15 | |
| 10 | 2019 | 19 | |
| 11 | 2019 | 8 | |
| 12 | 2018 | 10 | |
| 13 | 2017 | 34 | |
| 14 | 2015 | 7 | |
| 15 | 2011 | 32 | |
| 16 | 2003 | 32 | |
| 17 | 1997 | 26 | |
| 18 | 1996 | 6 | |
| 19 | 1995 | 7 | |
| 20 | 1994 | 16 |
About Maged Abdel Naseer
Maged Abdel Naseer is a scholar working on Pathology and Forensic Medicine, Neurology and Biological Psychiatry, having authored 28 papers that have together received 282 indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (15 papers), Peripheral Neuropathies and Disorders (3 papers), Protease and Inhibitor Mechanisms (3 papers), Neurological Disorders and Treatments (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Neurological Disease Mechanisms and Treatments (2 papers), Migraine and Headache Studies (2 papers) and Alzheimer's disease research and treatments (2 papers). The work is most often cited by research in Neurology (72 citations), Biological Psychiatry (21 citations) and Pathology and Forensic Medicine (84 citations). Maged Abdel Naseer has collaborated with scholars based in Egypt, Austria and Bahrain. Frequent co-authors include Amr Hassan, Hatem Shehata, Loutfy H. Madkour, Alaa Elmazny, Nirmeen A. Kishk, Sherif Hamdy, Nevin Shalaby, Mohamed Hegazy, Ahmed Abdelalim and Laila Ahmed Rashed. Their work appears in journals such as Multiple Sclerosis and Related Disorders, Journal of the Neurological Sciences, Therapeutics and Clinical Risk Management, Neurodegenerative Diseases and Neurological Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.